We are live on ! Find out more
CM

Crestline Management Portfolio holdings

AUM $46.3M
1-Year Est. Return 48.82%
This Fund
S&P 500
This Quarter Est. Return
+31.44%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$719M
AUM Growth
-$27.1M
Cap. Flow
-$214M
Cap. Flow %
-29.71%
Top 10 Hldgs %
66.29%
Holding
201
New
72
Increased
18
Reduced
27
Closed
81

Top Buys

Rank Stock Value
1
TRV icon
Travelers Companies
TRV
+$7.93M
2
FNB icon
FNB Corp
FNB
+$7.61M
3
SHW icon
Sherwin-Williams
SHW
+$7.06M
4
ALL icon
Allstate
ALL
+$5.58M
5
WTW icon
Willis Towers Watson
WTW
+$5.57M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$274M
2
CE icon
Celanese
CE
+$6.41M
3
MON
Monsanto Co
MON
+$6.27M
4
BG icon
Bunge Global
BG
+$5.97M
5
APD icon
Air Products & Chemicals
APD
+$4.65M

Sector Composition

Rank Sector Weight
1 Financials 19.98%
2 Industrials 5.93%
3 Healthcare 5.67%
4 Technology 4.78%
5 Communication Services 1.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CADE
101
DELISTED
Cadence Bank
CADE
$962K 0.13%
30,000
-5,000
-14% -$150K
PTCT icon
102
PTC Therapeutics
PTCT
$5.64B
$955K 0.13%
47,718
-50,071
-51% -$980K
STML
103
DELISTED
Stemline Therapeutics, Inc.
STML
$935K 0.13%
84,210
+104
+0.1% +$978
COUP
104
DELISTED
Coupa Software Incorporated
COUP
$909K 0.13%
+29,184
New +$890K
KALA icon
105
KALA BIO
KALA
$14.1M
$888K 0.12%
+16
New +$878K
FCN icon
106
FTI Consulting
FCN
$4.4B
$863K 0.12%
+24,318
New +$818K
CBAY
107
DELISTED
Cymabay Therapeutics
CBAY
$841K 0.12%
+104,392
New +$706K
RIGL icon
108
Rigel Pharmaceuticals
RIGL
$681M
$836K 0.12%
32,904
-14,265
-30% -$347K
CNO icon
109
CNO Financial Group
CNO
$5.14B
$797K 0.11%
34,151
– –
FAF icon
110
First American
FAF
$7.66B
$797K 0.11%
+15,954
New +$762K
FOLD
111
DELISTED
Amicus Therapeutics
FOLD
$797K 0.11%
+52,845
New +$699K
ARDX icon
112
Ardelyx
ARDX
$1.22B
$790K 0.11%
141,066
-70,661
-33% -$372K
ARRY
113
DELISTED
Array Biopharma Inc
ARRY
$729K 0.1%
+59,291
New +$551K
AXS icon
114
AXIS Capital
AXS
$7.68B
$703K 0.1%
+12,268
New +$757K
SSNC icon
115
SS&C Technologies
SSNC
$18.6B
$673K 0.09%
+16,751
New +$646K
HRTX icon
116
Heron Therapeutics
HRTX
$93.9M
$647K 0.09%
40,078
+3,058
+8% +$48K
SNDX icon
117
Syndax Pharmaceuticals
SNDX
$1.69B
$626K 0.09%
53,532
-1,836
-3% -$22.5K
CPRX
118
DELISTED
Catalyst Pharmaceutical
CPRX
$562K 0.08%
+223,019
New +$612K
GHL
119
DELISTED
Greenhill & Co., Inc.
GHL
$534K 0.07%
+32,178
New +$544K
FATE icon
120
Fate Therapeutics
FATE
$286M
$96K 0.01%
+24,174
New +$82.2K
ACGL icon
121
Arch Capital
ACGL
$34.3B
– –
-48,606
Closed -$1.51M
ADM icon
122
PUT
Archer Daniels Midland
ADM
$38.2B
– –
-2,000
Closed -$345K
AJG icon
123
Arthur J. Gallagher & Co
AJG
$64.1B
– –
-66,345
Closed -$3.8M
AKBA icon
124
Akebia Therapeutics
AKBA
$354M
– –
-35,098
Closed -$504K
ALNY icon
125
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-10,814
Closed -$863K
3 4
5
6 7

Similar funds

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
RRC
Range Rock Capital Wellesley, Massachusetts $46.7M AUM
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
NPCM
New Paradigm Capital Management Great Falls, Virginia $46.8M AUM
FCM
Firsthand Capital Management San Jose, California $46.9M AUM 114.33% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
IPHI
Inflection Point Holdings II New York $47.3M AUM
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Crestline Management's Q3 2017 Portfolio in Review

As of Q3 2017, Crestline Management held 201 positions worth $719M, down 3.6% from $746M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Crestline Management withdrew a net $214M in Q3 2017, closing 81 positions and reducing 27 holdings. Its most notable exit was Celanese, an estimated $6.41M position sold in full.

By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 13% a quarter earlier, followed by Industrials and Healthcare.

Against the trend, Crestline Management opened a new position in Travelers Companies worth $7.78M.

  • Crestline Management's largest Q3 2017 buy was Travelers Companies: 63,503 shares worth $7.78M.
  • Crestline Management added most to FNB Corp in Q3 2017, an estimated $7.61M increase.
  • Crestline Management's biggest Q3 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $274M.
  • Crestline Management fully exited Celanese in Q3 2017, selling an estimated $6.41M.
  • Crestline Management's ten largest holdings make up 66% of its $719M portfolio in Q3 2017.
  • Crestline Management opened 72 new positions and closed 81 in Q3 2017.
  • Crestline Management's portfolio value fell 3.6% quarter-over-quarter to $719M.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.